Intellia Therapeutics, Inc. NTLA

NTLA Company Overview

Intellia Therapeutics, Inc. is a biotechnology company focused on developing gene-editing therapies using CRISPR/Cas9 technology. The company operates within the biotechnology, genetic medicine, and genomic editing industries, with a primary emphasis on creating potentially curative therapies for severe diseases with high unmet medical need. Intellia’s core business centers on in vivo and ex vivo gene editing approaches, with its research and development activities targeting hereditary diseases, immunological disorders, and oncology applications. The company’s principal revenue sources have historically included collaboration agreements, licensing arrangements, and research funding partnerships, while its long-term strategy is centered on commercialization of therapeutic candidates.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Intellia emerged from foundational CRISPR research developed by scientific pioneers including Jennifer Doudna and collaborators associated with Caribou Biosciences. The company became publicly traded on Nasdaq under the ticker NTLA in 2016. Intellia has positioned itself as one of the early leaders in systemic in vivo CRISPR-based therapeutics, particularly through lipid nanoparticle delivery systems designed to edit genes directly inside the body. Its differentiation has been associated with proprietary genome-editing platforms, intellectual property access, and early clinical development progress in transthyretin amyloidosis and hereditary angioedema programs.